Light shouldn't hurt. For most people it doesn't — the room you are reading this in is probably "normal lighting," unremarkable enough to not register. For some readers, that same room is already too bright. For others, this paragraph is being read at minimum brightness, in a corner with the blinds down, with sunglasses on indoors, or with eyes closed between sentences. If that is you, you already know what photophobia is. The rest of this post is for the people in your life who don't yet — and for you, when you would like a citation to hand them.
Photophobia — light sensitivity — is a documented neurological and ophthalmologic symptom with measurable biology. It affects millions across migraine, post-concussion syndrome, dry-eye disease, iris injury, blepharospasm, achromatopsia, and a long tail of less common conditions. It is not "an exaggeration." It is not "in your head" in the dismissive sense. It is in your head in a specific anatomical sense — there is a circuit, it has been mapped, and the people who live with it are reading their own pathway accurately.
This post is about what the circuit is, what conditions reliably engage it, and where a contrast-sensitivity measurement does and doesn't sit in the picture.
What photophobia is — and isn't
Photophobia is a painful or aversive response to light intensities most people tolerate without discomfort. The clinical bar is not "I squinted walking out of a movie theatre" — that is normal visual aversion, the eye-protecting reflex everyone has stepping into bright sun. Photophobia is when modest indoor lighting feels harsh; when supermarket fluorescents trigger a headache within minutes; when sunlight off a wet road is unbearable rather than annoying; when a phone screen at minimum brightness still hurts.
It is usually a symptom of an underlying condition rather than a condition itself. The clinical workup is not to "treat photophobia" in isolation but to identify what is producing it — and then manage the underlying problem (migraine prevention, post-concussion rehab, dry-eye therapy) alongside the symptom. The exception is idiopathic photophobia, where no underlying cause is found — a real diagnosis, just an unsatisfying one.
Digre and Brennan's 2012 review in the Journal of Neuro-Ophthalmology — still one of the cleaner walk-throughs of the topic — separates the symptom into discomfort (light feels harsh), pain (light causes head or eye pain on its own), and exacerbation (light makes existing headache worse). Most patients with severe photophobia describe a mix, and the underlying biology probably differs across the categories (Digre & Brennan, 2012).
The circuit — ipRGCs to the trigeminal pain system
The cleanest piece of photophobia neuroscience in the last two decades came out of Rami Burstein's lab at Harvard. In a 2010 Nature Neuroscience paper, Noseda, Kainz, Burstein and colleagues asked a question that had been hanging in the air for years: why does light make a migraine headache worse, including in people who are otherwise blind?
The headline finding is that the brain has two largely separate ways of using retinal signals. The familiar one — the image-forming pathway — runs from rods and cones through the lateral geniculate nucleus to visual cortex, producing the experience of seeing. The other is a non-image-forming pathway built around a small class of cells called intrinsically photosensitive retinal ganglion cells, or ipRGCs. ipRGCs contain a pigment called melanopsin, are most sensitive to short-wavelength light around 480 nm, and project to brain regions that have nothing to do with conscious vision: the suprachiasmatic nucleus (the circadian clock), the olivary pretectal nucleus (the pupillary light reflex), and — Noseda et al.'s key finding — a population of dura-sensitive neurons in the posterior thalamus that relay pain signals from the meninges to the cortex (Noseda et al., 2010).
That last projection is the photophobia circuit. Light hitting the retina is, in this pathway, not "an image" — it is a modulating input to a pain-processing pipeline. In a sensitised brain (mid-attack migraine, persistent post-concussion changes) that modulation registers as pain, or as exacerbation of pain already in progress. The 2010 paper made the case by showing that blind people who had lost rods and cones but retained ipRGC function still experienced light-driven worsening of migraine headache, while those who had lost the entire optic nerve did not.
A few years later, the same group complicated this nicely. Noseda et al. 2016, in Brain, showed that narrow-band green light actually reduces migraine pain, while blue, amber and red light all worsen it (Noseda et al., 2016). Amber and red worsening pain implicates cone-driven pathways, not just melanopsin — the simple "ipRGCs alone do this" story isn't quite right. The honest model: there is a non-image-forming circuit from retina to trigeminal pain regions, ipRGCs are part of it, cones contribute too, and wavelength dependence is more complex than any single-cell story.
A line against a related story on this site: the post on screens at night covers ipRGCs projecting to the suprachiasmatic nucleus and suppressing melatonin — same cell class, different downstream target (circadian, not nociceptive). One projection is about sleep timing. The other is about headache.
The conditions that engage this circuit
Photophobia is a feature of a long list of conditions. The most common, by patient volume:
Migraine. Photophobia is a diagnostic criterion for migraine in the ICHD and is reported by over 80% of patients during attacks. A meaningful subset also experiences interictal photophobia — light sensitivity between attacks — consistent with the broader cortical hyperexcitability story in the migraine literature. Our migraine-and-contrast post covers that angle in more depth.
Post-concussion syndrome. Merezhinskaya and colleagues' 2021 meta-analysis in Optometry and Vision Science pooled 75 studies of photophobia after traumatic brain injury and found prevalence of about 30% one week after injury, falling to roughly 13% by three months. Patients with TBI were nearly six times more likely than controls to report photophobia, with elevated risk persisting to at least a year post-injury (Merezhinskaya et al., 2021). For a meaningful minority, the symptom does not resolve at the pace of the rest of the picture.
Dry-eye disease. Less obvious — most people associate dry eye with stinging, scratchiness, or blurred vision — but a substantial fraction of patients with moderate-to-severe dry eye describe genuine photophobia. Diel and colleagues' 2021 British Journal of Ophthalmology review argues that chronic ocular-surface inflammation sensitises corneal nociceptors, which feed into the same trigeminal pathway the ipRGC circuit modulates — convergence and cross-talk at the trigeminal nucleus and thalamus (Diel et al., 2021). The paper makes the broader case that dry eye, migraine, and post-TBI photophobia may share a final common pathway of trigeminothalamic neuroplasticity — a useful unifying frame.
Other. Iris injury (damage to the structure that regulates light entry makes any light feel piercing). Acute uveitis (intraocular inflammation — a medical urgency). Benign essential blepharospasm (involuntary eyelid spasms often paired with severe light sensitivity). Albinism and achromatopsia (peripheral — too little iris pigment, absent cone function). Some antibiotic and antihistamine medications. Idiopathic, when nothing else fits.
The list matters because it points at the right clinician. Photophobia plus headaches argues for neurology; plus eye pain and redness, for ophthalmology, urgently if uveitis is possible; plus a head-injury history, for neuro-optometric rehabilitation; plus burning, gritty, fluctuating vision, for the dry-eye workup.
Where does contrast sensitivity sit in this picture?
Honestly: in a different place than photophobia, with some overlap.
The pathway this post has described is non-image-forming. Conscious vision — the part that lets you read this sentence, recognise faces, see the edge of a kerb — runs through a different anatomy (retina → LGN → visual cortex). A contrast-sensitivity measurement samples the conscious-vision pathway; a photophobia threshold (the lowest light intensity that triggers symptoms, measurable clinically with the right equipment) samples the trigeminal pathway. Separate channels.
But — the connection patients often notice on their own — the conditions that produce photophobia frequently also affect the conscious-vision pathway. Migraine cohorts show interictal contrast-sensitivity differences in many published studies. Post-concussion patients commonly show both photophobia and mid-spatial-frequency CSF reductions. Long-standing severe dry eye degrades contrast through tear-film instability that scatters light entering the eye, before the trigeminal sensitisation story even begins. The same condition can engage both pathways at once — which is why "the world looks somehow flatter and the lights also hurt more" is typically a real co-occurrence rather than an illusion.
What this means for an at-home test: a contrast-sensitivity result does not measure your photophobia. There is no online instrument we know of that does — clinically, photophobia thresholds are measured under controlled luminance with calibrated stimuli, and we would not want to recreate that on a consumer screen. If you have photophobia AND a reduced contrast-sensitivity curve, those are two related signals worth bringing together to a neuro-ophthalmologist, headache specialist, or neuro-optometrist.
What helps
Photophobia management runs on several tracks at once. Most of the work is on the underlying condition: migraine prevention reduces ictal photophobia; concussion rehab typically improves it over months; dry-eye treatment improves the ocular-surface contribution. A few interventions work on the symptom directly.
FL-41 tinted lenses are the longest-studied option for migraine-related photophobia. FL-41 is a rose-tinted spectacle coating originally developed in the late 1980s to reduce sensitivity to fluorescent lighting; it absorbs primarily in the 480–520 nm band — overlapping the spectrum implicated in the non-image-forming pathway. The seminal trial was Good and colleagues' 1991 study in Headache of 20 children with migraine, which reported a reduction in attack frequency from about 6.2 to 1.6 per month with FL-41 lenses (Good, Taylor & Mortimer, 1991). FL-41 has also been studied in benign essential blepharospasm with reduction in light-triggered spasms. We don't sell glasses; we mention FL-41 because it is the option a neuro-ophthalmologist or headache specialist is most likely to bring up, and patients deserve to know it exists.
A few practical others, less research-based but with broader clinical consensus:
- Wraparound sunglasses outdoors, polarised if glare from water or wet pavement is a trigger.
- Avoid fluorescent and high-CCT (cool) lighting where you can. Warm-white LEDs (≤3000K) are usually better tolerated than cool-white. Older fluorescent fixtures with visible flicker are particularly aggravating in migraine.
- Dim ambient lighting to the lowest level that lets you function; on screens, use night-shift and the lowest brightness that lets you read. The point isn't darkness as a permanent state; it's not needing to recruit the photophobia circuit just to look at your laptop.
- Sunglasses indoors are not a moral failing. Some patients with severe persistent photophobia need them. The literature's caution is to avoid permanent dark adaptation (it can worsen photophobia long-term) but to use tinted lenses as needed during flares.
The right combination depends on the underlying condition; this is a "what's in the toolkit" overview, not a treatment plan.
What our test can and can't tell you
Note. A contrast-sensitivity test does not measure photophobia.
The two run on largely separate pathways. A normal contrast-sensitivity result does not say anything about whether your light sensitivity is "real," and a reduced result is not a photophobia score. There is no online test we are aware of that quantifies photophobia thresholds reliably; that measurement belongs in a clinic with calibrated luminance equipment.
A reduced CSF curve combined with photophobia is, at most, a pair of related observations worth bringing to a specialist together — not a diagnosis, not a verdict, and not a stand-in for the clinical workup the underlying condition deserves.
If you have photophobia and you'd like an objective contrast-sensitivity reading to bring alongside it, that's a perfectly reasonable thing to do — same caveats as for any patient with a chronic neurological symptom. Test in lighting that is comfortable for you; if testing on a typical mid-grey screen would itself trigger symptoms, don't. Your comfort during the measurement is a higher priority than the measurement itself.
Where to go next
If photophobia is new, severe, or accompanied by red eye, eye pain, fever, or any sudden vision change, that is a same-day medical contact — acute uveitis, optic neuritis, and other causes need urgent attention.
If photophobia is part of an existing picture (migraine, post-concussion, dry eye), the right next step is the clinician who already manages that condition. Bring concrete examples: which environments are worst, how long episodes last, what helps. If FL-41 or tinted lenses haven't been discussed, that is a reasonable thing to raise.
For the contrast-sensitivity thread: take the test in a sitting where the brightness isn't pushing you. Save the result. Repeated in similar conditions over weeks, the trend may be worth bringing to the specialist — alongside, not instead of, the photophobia history.
Take the test
Photophobia is not exaggeration. It is a documented circuit doing its job in a context where its job has become a problem. If you also have a question about how clearly you're seeing — contrast, faces, screens, edges — the test gives you one objective number to bring alongside the rest of the picture.
The first reading is a snapshot. The second is the start of a line.
References
- Noseda, R., Kainz, V., Jakubowski, M., Gooley, J. J., Saper, C. B., Digre, K., & Burstein, R. (2010). A neural mechanism for exacerbation of headache by light. Nature Neuroscience, 13(2), 239–245. Foundational paper mapping the non-image-forming retinal pathway responsible for light-induced exacerbation of migraine headache. Showed in rat single-unit and tract-tracing experiments that dura-sensitive thalamic neurons receive direct retinal input, and that blind humans with intact ipRGCs still experience light-driven worsening of migraine pain while those without retinal output do not.
- Noseda, R., Bernstein, C. A., Nir, R. R., Lee, A. J., Fulton, A. B., Bertisch, S. M., Hovaguimian, A., Cestari, D. M., Saavedra-Walker, R., Borsook, D., Doran, B. L., Buettner, C., & Burstein, R. (2016). Migraine photophobia originating in cone-driven retinal pathways. Brain, 139(7), 1971–1986. Wavelength-resolved study showing that narrow-band green light reduces migraine headache pain while blue, amber and red light all worsen it. Implicates cone-driven retinal pathways in addition to melanopsin/ipRGC contributions — complicates the simpler "ipRGCs alone drive photophobia" model.
- Digre, K. B., & Brennan, K. C. (2012). Shedding light on photophobia. Journal of Neuro-Ophthalmology, 32(1), 68–81. Comprehensive clinical review of photophobia across ophthalmic and neurologic disorders. Separates discomfort, pain, and exacerbation categories; surveys the anatomy and physiology of the symptom; offers a practical approach to clinical assessment and management.
- Merezhinskaya, N., Mallia, R. K., Park, D., Millian-Morell, L., & Barker, F. M. (2021). Photophobia associated with traumatic brain injury: a systematic review and meta-analysis. Optometry and Vision Science, 98(8), 891–900. Pooled 75 studies covering photophobia after traumatic brain injury. Prevalence 30.46% at one week post-injury, 19.34% between one week and one month, 13.51% between one and three months, with elevated risk versus controls (OR ~5.75) persisting to at least one year post-injury.
- Diel, R. J., Mehra, D., Kardon, R., Buse, D. C., Moulton, E., & Galor, A. (2021). Photophobia: shared pathophysiology underlying dry eye disease, migraine and traumatic brain injury leading to central neuroplasticity of the trigeminothalamic pathway. British Journal of Ophthalmology, 105(6), 751–760. Synthesises the trigeminothalamic-sensitisation model that unifies photophobia across dry eye disease, migraine, and post-TBI presentations — useful for understanding why these populations report overlapping symptom patterns despite different proximate causes.
- Good, P. A., Taylor, R. H., & Mortimer, M. J. (1991). The use of tinted glasses in childhood migraine. Headache, 31(8), 533–536. Original FL-41 trial in 20 children with migraine — reported reduction in attack frequency from approximately 6.2 to 1.6 per month with FL-41-tinted spectacles. The reference cited in most subsequent FL-41 reviews; the evidence base since has broadened to adult migraine and benign essential blepharospasm.